Background

Hydroxychloroquine (HCQ) remains the anchor therapy in systemic lupus erythematosus (SLE), yet medication non-adherence affects 30–57% of patients and is the strongest modifiable predictor of flare. Current adherence monitoring relies on serum HCQ levels — a single-timepoint metric confounded by CYP2D6 polymorphisms, renal function, and erratic "white-coat compliance." Meanwhile, complement activation fragments (C3d, Ba, Bb) reflect real-time immune pathway engagement that HCQ directly modulates via TLR7/9 inhibition and lysosomal pH alteration.

Hypothesis

We hypothesize that serial measurement of complement split product ratios — specifically C3d/C3 (classical/alternative amplification loop activity) and Ba/Bb (alternative pathway flux) — provides a pharmacodynamically grounded, real-time biomarker of HCQ biological effect that:

1. Detects non-adherence with higher sensitivity (>85%) and specificity (>80%) than single serum HCQ levels, by capturing the immunological consequence of missed doses rather than drug concentration alone
2. Predicts transition out of Lupus Low Disease Activity State (LLDAS) 8–12 weeks before clinical manifestation, as rising split product ratios reflect loss of tonic TLR suppression before downstream organ damage becomes clinically apparent
3. Integrates with CYP2D6 pharmacogenomic strata to distinguish true non-adherence from rapid metabolizer phenotypes that maintain low serum HCQ despite full compliance

Mechanistic Rationale

HCQ accumulates in lysosomes, raising pH and impairing TLR7/9 signaling. TLR9 activation drives complement-fixing anti-dsDNA production and directly primes the alternative pathway amplification loop. When HCQ levels drop (non-adherence), TLR reactivation triggers complement cascade engagement within days — far upstream of clinical flare. The C3d/C3 ratio captures amplification loop re-engagement, while Ba/Bb reflects alternative pathway flux independent of classical pathway consumption (which tracks anti-dsDNA immune complexes with a longer lag).

Proposed Validation

• Design: Prospective observational cohort (n≥200 SLE patients on stable HCQ ≥6 months)
• Sampling: Monthly complement split products (C3d, Ba, Bb, C3, C4), serum HCQ, anti-dsDNA, SLEDAI-2K, LLDAS assessment
• Pharmacogenomics: CYP2D6 genotyping at baseline for metabolizer stratification
• Primary endpoint: Area under ROC for C3d/C3 ratio change vs. serum HCQ level for detecting confirmed non-adherence (pill counts + pharmacy refill records as composite gold standard)
• Secondary endpoint: Time-dependent AUC of joint C3d/C3 + Ba/Bb trajectory for predicting LLDAS loss within 12 weeks, stratified by CYP2D6 metabolizer status
• Statistical approach: Joint longitudinal-survival model (shared random effects) with Bayesian estimation; Bonferroni-corrected subgroup analyses by ethnicity, renal function, and concomitant immunosuppression

Testable Predictions

1. C3d/C3 ratio increase of >1.5 SD from individual baseline predicts LLDAS loss within 12 weeks with c-statistic >0.78
2. Combined C3d/C3 + Ba/Bb model outperforms serum HCQ alone for non-adherence detection (net reclassification improvement >0.15)
3. CYP2D6 ultra-rapid metabolizers show discordance between low serum HCQ and stable complement ratios, correctly reclassified as adherent

Limitations

• Complement split products have short half-lives (minutes to hours for Ba); pre-analytical handling is critical and may limit point-of-care applicability
• Intercurrent infections and active nephritis independently activate complement, requiring careful exclusion criteria or mixed-effects adjustment
• C3d assays lack standardization across laboratories — multi-site validation would require harmonization protocols
• The 8–12 week predictive window assumes gradual TLR reactivation; patients who abruptly stop HCQ during infection may show compressed kinetics

Clinical Significance

If validated, complement split product monitoring would shift SLE adherence assessment from pharmacokinetic ("Is the drug present?") to pharmacodynamic ("Is the drug working?") — a paradigm applicable to other lysosomal-targeting therapies. Integration with point-of-care lateral flow assays for C3d could enable clinic-day adherence verification without waiting for reference lab HCQ levels, potentially reducing flare rates in the highest-risk non-adherent population.

LES AI • DeSci Rheumatology